Malaria booster vaccine: update

Malaria is a leading cause of morbidity and mortality worldwide.

Researchers reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™

In their findings, they found that a vaccine booster dose at one year following a primary three-dose regime maintained high efficacy against malaria.

The findings offer hope that the vaccine, called R21, could be an effective weapon in the fight against malaria, which is one of the biggest killers globally.

The co-inventor of a vaccine said he hopes it could be approved by as early as next year after the latest trial results were successful.

Professor Adrian Hill,  believes R21 could help to reduce deaths from the disease by 70% by 2030 and eradicate it by 2040.

This double-blind phase 1/2b randomised controlled trial was done in children aged 5–17 months in Nanoro, Burkina Faso.

he R21 vaccine has been tested in 450 children aged between 5 and 17 months in Burkina Faso, a country in which malaria infections are seasonal.

This study published in The lancet infectious diseases

Reference click here